Aetna Updates Commercial Drug Lists

April 2018 ~

Effective July 1, Aetna will update its pharmacy plan drug lists. These changes will affect all Pharmacy Management drug lists, precertification, quantity limits and step-therapy programs.

These changes are as follows:

• Granulocyte-Colony Stimulating Factor Products
  • Granix^® (injection tbo-filgrastim)
  • Leukine^® (injection sargramostim, GM-CSF)
  • Neulasta^® (injection pegfilgrastim)
  • Neupogen^® (injection filgrastim, G-CSF)
  • Zarxio^® (injection filgrastim, G-CSF, biosimilar)
• As of July 1, 2018, Zarxio^® will be considered the least costly short-acting granulocyte colony-stimulating factor (G-CSF) product.
• All G-CSFs will remain on the National Precertification List and require precertification.
• Coverage for Neupogen^® and Granix^® will require a trial of Zarxio^® and will also need to meet the clinical precertification criteria.
• Neulasta^® will not be affected by this change.

A list of these changes can be seen on Aetna’s Formularies & Pharmacy Clinical Policy Bulletins page. Note: for Aetna Standard Plan, these changes will be made available in May 2018.

Source(s): Aetna OfficeLink Updates^™ All regions;